The Roanoke Heart Institute emphasizes the application of advanced pharmacological means of prevention as well as treatment of cardiovascular diseases. We always use proven therapies first at the RHI. However, you may also have access to new tests or treatments under clinical investigation in studies either sponsored through the National Institutes of Health or by reputable companies in the pharmaceutical industry, as approved by the Food and Drug Administration.
New tests and treatments are only used with your consent. Our active studies are listed below for your information. Note that there are detailed inclusion and exclusion criteria for each study, and these will be examined if you otherwise qualify for participation.
TACT2 “A randomized, double blind controlled factorial clinical trial of edetate disodium-based chelation and high-dose oral vitamins and minerals to prevent recurrent cardiac events in diabetic patients with a prior myocardial infarction.” Sponsor: National Institutes of Health / Mount Sinai Medical Center / Columbia University Medical Center. More Information.
AURORA “A Phase 3, Open-Label, Multicentre Study of Flurpiridaz (18F) Injection for Positron Emission Tomography (PET) Imaging for Assessment of Myocardial Perfusion in Patients Referred for Invasive Coronary Angiography Because of Suspected Coronary Artery Disease.” The study will be performed in partnership with LewisGale Medical Center. Sponsor: General Electric. More Information.
CLEAR “A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients with, or at High Risk for, Cardiovascular Disease who are Statin Intolerant.” Sponsor: Esperion Therapeutics. More Information.
EMPEROR-Preserved “A Phase III Randomised, Double-Blind Trial to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg Compared to Placebo, in Patients with Chronic Heart Failure with Preserved Ejection Fraction. Sponsor: Boehringer Ingelheim. More Information.
PROMINENT “Pemafibrate to Reduce Cardiovascular Outcomes By Reducing Triglycerides in Patients with Diabetes.” Sponsor: Kowa Research Institute. More Information.
THEMIS “A multinational, randomised, double-blind, placebo-controlled phase IIIb trial to evaluate the effect of ticagrelor twice daily on the incidence of cardiovascular death, myocardial infarction or stroke in patients with type 2 diabetes mellitus.” Sponsor: AstraZeneca. Enrollment completed. More Information.